Cognitive & Mood
Selank
Selank (TKPRPGP)
Russian-developed nootropic peptide for anxiety and cognition
- FDA Status
- Not FDA-approved · Approved in Russia
- Class
- Heptapeptide · synthetic analog of tuftsin
- Sequence
- Thr-Lys-Pro-Arg-Pro-Gly-Pro
- Half-life
- ~30 min (intranasal)
Mechanism of action
- GABA-A receptor modulation (anxiolytic)
- BDNF (brain-derived neurotrophic factor) upregulation
- Enkephalin system modulation
- Immune modulation via tuftsin analog activity
Research areas
- Generalized anxiety disorder
- Cognitive enhancement and stress adaptation
- Immune support during cold/flu
- PTSD and trauma-related research (Russian studies)
Evidence and clinical data
Russian clinical trials (translated literature). Western Phase I/II data is limited. Intranasal formulation has best documented bioavailability.
Safety profile
Excellent reported tolerability. Limited Western pharmacovigilance. No major adverse events in Russian post-market surveillance.
Why this peptide is trending in 2026: Part of the "Russian nootropic peptides" interest (alongside Semax). Anxiolytic effect without benzodiazepine-class dependency profile.
Educational use only. PeptideAdvance does not sell Selank, recommend its use, or provide medical advice. The information above is a summary of published research and regulatory status as of April 2026. Some peptides discussed here are not FDA-approved or are restricted under FDA Category 2 — their use outside of authorized clinical research may carry legal and safety implications. Always consult a licensed healthcare professional.